A Clinical Trial of PD-L1 Inhibitor Durvalumab and PARP Inhibitor Olaparib for Patients With EGFR-Mutated Transformed SCLC

Large LDCT Lung Cancer Screening Program Suggests Screening Benefits Far Outweigh the Risks

Possible Benefits of Metformin for Lung Cancer Still Unknown

Tyrosine kinase inhibitors (TKI) or monoclonal antibodies (mAb) for the Treatment of NRG1 and, Potentially, NRG2 Fusion–Positive Malignancies

Vemurafenib Alone and Combination for Lung Cancer: A Conversation with Marcelo V. Negrao, MD

Premonitions About Lung Cancer for the Next Decade 

Pyrotinib: A Potential New Anti-HER2 Therapy for Lung Cancer

LGBT Cancer Survivors and Disparities-Related Barriers That May Affect Survival

Addressing Lung Cancer Screening Disparities in the LGBT Community

Study Identifies Lung Cancer Areas of Improvement Across Asia-Pacific Region

Examining Value and Access in Lung Cancer Care, From Screening to Treatment

Revised U.S. Food and Drug Administration Trial Eligibility Guidance: A Major Step Toward Transforming Lung Cancer Clinical Trials